Submicroscopic deletions involving chromosome 1q43-q44 result in cognitive impairment, microcephaly, growth restriction, dysmorphic features, and variable involvement of other organ systems. A consistently observed feature in patients with this deletion are the corpus callosal abnormalities (CCAs), ranging from thinning and hypoplasia to complete agenesis. Previous studies attempting to delineate the critical region for CCAs have yielded inconsistent results. We conducted a detailed clinical and molecular characterization of seven patients with deletions of chromosome 1q43-q44. Using array comparative genomic hybridization, we mapped the size, extent, and genomic content of these deletions. Four patients had CCAs, and shared the smallest region of overlap that contains only three protein coding genes, CEP170, SDCCAG8, and ZNF238. One patient with a small deletion involving SDCCAG8 and AKT3, and another patient with an intragenic deletion of AKT3 did not have any CCA, implying that the loss of these two genes is unlikely to be the cause of CCA. CEP170 is expressed extensively in the brain, and encodes for a protein that is a component of the centrosomal complex. ZNF238 is involved in control of neuronal progenitor cells and survival of cortical neurons. Our results rule out the involvement of AKT3, and implicate CEP170 and/or ZNF238 as novel genes causative for CCA in patients with a terminal 1q deletion.
INTRODUCTION
Submicroscopic deletions involving the distal region of chromosome 1q result in a complex phenotype that includes growth restriction, microcephaly, craniofacial dysmorphisms, significant cognitive impairment, hypotonia, and corpus callosal abnormalities (CCAs). [1] [2] [3] [4] [5] [6] CCAs, ranging from thinning and hypoplasia to complete agenesis, are consistently observed in deletions involving terminal 1q. [1] [2] [3] [4] [5] [6] Previous studies have suggested that the deletion of the most telomeric part of the long arm of chromosome 1, 1q43-q44, is responsible for the CCAs. However, narrowing the critical region responsible for CCAs has yielded inconsistent results. 1,6-9 Boland et al 8 mapped the deletion and translocation breakpoints in 1q44, and suggested that haploinsufficiency of AKT3 is responsible for the CCAs (Figure 1 ). However, Poot et al 9, 10 described CCAs in a patient with terminal deletion of 1q44, without involvement of AKT3. A subsequent study by van Bon et al 1 narrowed the critical region for CCAs containing only C1orf100, ADSS, C1orf101, and PNAS-4. A more recent study hypothesized the gene HNRPU that is telomeric to the critical region mapped by van Bon et al 1 , is causative of CCAs (Figure 1 ). 6 Using a reverse genomic approach, we sought to better understand the genotype -phenotype correlations, and map the critical region for CCAs in patients with deletion of 1q43-q44. 11 The Medical Genetics Laboratories at Baylor College of Medicine (BCM) has performed over 14 000 array comparative genomic hybridization (aCGH) for clinical evaluation of subjects with developmental delay, dysmorphic features, and/or multiple congenital anomalies from June 2007 to January 2011. From this cohort of patients, we identified seven patients with deletions of 1q43-q44 including one patient with an intragenic deletion of AKT3. In this report, we describe the delineation of a critical region for CCAs and show that deletion of a region spanning B930 kb between genomic coordinates 241 054 360-241 522 998 and 241 936 310-242 398 193 (NCBI36/hg18) is responsible for the CCAs (Figure 1 ).
METHODS

Human subjects
Identification of 1q43-q44 deletions was made by clinical diagnostic testing using aCGH. Clinical information was obtained from health care providers, using a checklist to standardize the data collection. The protocol was approved by the Institutional Review Board for human subjects' research at BCM.
Array comparative genomic hybridization
We performed aCGH analysis on the clinical microarray platform routinely used in our institution. The microarrays were designed in the Medical Genetics Laboratory of BCM. All of the patient samples were interrogated using V8.OLIGO (180K). The V8.OLIGO is a custom-designed array with approximately 180 000 (60 mer) interrogating oligonucleotides, manufactured by Agilent Technologies, Inc. (Santa Clara, CA, USA). This array contains the 'bestperforming' oligonucleotides (oligos) selected from Agilent's online library (eArray; https://earray.chem.agilent.com/earray/) and has been further optimized using empiric data. This array is designed to provide interrogation of all known microdeletion and microduplication syndrome regions, as well as pericentromeric and subtelomeric regions as previously described. 12 In addition, 1784 genes either known to cause or hypothesized as candidate genes for various clinical phenotypes have exonic coverage with an average of 4.2 probes per exon, as well as introns greater than 10 kb. The entire genome is covered with an average resolution of 30 kb, excluding low-copy repeats and other repetitive sequences (https://www.bcm.edu/geneticlabs/). The procedures for DNA digestion, labeling, hybridization, and data analysis, were performed as previously described. 13 
RESULTS
Array comparative genomic hybridization
The deletions ranged in size from 0.08 to 4.35 Mb ( Table 1) . The deletions in patients 1-3 were confirmed to be de novo, the deletion in patient 7 was inherited from a clinically asymptomatic mother, whereas the inheritance pattern in the remaining three patients could not be ascertained due to non-availability of both parental samples. All deletions involved at least a portion of the AKT3 gene, except for patient 7. Two deletions were intragenic; the first disrupted AKT3 gene in patient 5, and the second disrupted SMYD3 gene in patient 7 ( Figure 1 ). All deletions were confirmed by FISH analysis (data not shown). We did not detect any other copy number variations that could confound the interpretation of the data.
Clinical features
The clinical features of patients are summarized in Table 2 . As the mother of patient 7 did not have phenotypic consequences, patient 7 was excluded from analysis. Patients with deletions of 1q43-q44 predominantly presented with a neuro-cognitive phenotype with developmental delay involving gross motor, fine motor, and language faculties. Microcephaly and/or structural abnormalities of the brain were observed in all, except patient 6. CCAs ranging from severe thinning to complete agenesis were seen in patients 1 through 4, whereas patients 5 and 6 with small deletions did not have any CCAs. Congenital heart disease in the form of atrial septal defect, Tetralogy of Fallot, and ventricular septal defect were noted in patients 3, 4, and 5, respectively. Craniofacial dysmorphic features were generally mild, with no characteristic facial gestalt.
DISCUSSION
Submicroscopic deletions involving the terminal portion of chromosome 1q43-q44 have recently emerged as a recognizable phenotype. The deletions in this region are the most common CNV associated with CCAs, and 35 patients have been reported to date. 14 Previous studies attempting to map the critical region for CCAs observed with the deletions of this region have yielded inconsistent results. Boland et al 8 studied patients with unbalanced structural rearrangements of distal 1q, and narrowed down a 3.5-Mb critical region that they hypothesized to contain the gene responsible for CCA. By further mapping of a t(1;13)(q44;q32) in a patient with microcephaly and CCA, they demonstrated a breakpoint mapping 20 kb upstream of AKT3, a serine-threonine kinase, and suggested that haploinsufficiency of this gene was responsible for CCA. Orellana et al 7 described a patient with a de novo small interstitial 1q44 deletion mapping from ADSS to KIF26B, with a mild phenotype and absence of CCA consistent with a critical region encompassing AKT3 or ZNF238 genes in corpus callosum development. Two targeted Akt3 knockout mouse models have been described, 15, 16 and one demonstrated callosal hypoplasia 16 with loss of both copies of Akt3. These data suggested that deletion of AKT3 is responsible for CCAs. The red bars depict the deletions in our cohort of patients, with blue stars adjacent to the bars representing the patients with CCAs, and the green triangles depicting the patients with microcephaly. The blue colored genomic interval that encompasses CEP170 and ZNF238 is the critical region for CCAs, whereas the green interval depicts that loss of AKT3 is critical for microcephaly. The previously mapped regions for CCA by Boland et al 8 , van Bon et al 1 and Caliebe et al 6 are depicted at the bottom. The deletions in patients 1-3 were confirmed to be de novo, the deletion in patient 7 was inherited from a clinically asymptomatic mother, whereas the inheritance pattern in the remaining three patients could not be ascertained.
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However, in a case report by Poot et al, 10 a patient with a terminal 1q44 deletion that spared both ZNF238 and AKT3 did have CCA, implying that AKT3 may not be causative of this abnormality. van Bon et al 1 in their cohort of 13 patients with the submicroscopic 1q43-q44 deletions delineated a region that was telomeric to and excluding AKT3, mapping from C1orf100 to PNAS-4 for CCAs. Caliebe et al 6 showed that their cohort of four patients with a terminal 1q deletion and CCA shared a 0.44-Mb region of overlap, containing the genes FAM36A, HNRPU, EFCAB2, and KIF26B, telomeric to the one mapped by van Bon et al (Figure 1 ). Although these studies implied that AKT3 maps outside of the region(s) critical for CCA, they do not address the question as to whether these deletions telomeric to AKT3 affect the transcription of AKT3. The data represent the location of breakpoints and the size of the deletions as assessed by V8.OLIGO.
Our study reports an intragenic deletion of AKT3 in a patient with no evidence of CCAs, conclusively showing that haploinsufficiency of this gene is not responsible for this abnormality. The deletion in patient 2 is the smallest one amongst our patients with CCA. As patients 5 and 6 do not have any CCA, the region between genomic coordinates 241 054 360 and 241 522 998, centromeric to AKT3 encompassing CEP170, and the region between 241 936 310 and 242 398 193 containing ZNF238 is likely critical for development of CCA (Figure 1) . CEP170 is expressed extensively in the brain and encodes for a protein that is a component of the centrosomal complex that is involved in maintaining microtubule organization and function. Centrosomal proteins have a well-known function in neurogenesis, and have been hypothesized as important genes for the evolution of human brain size. Mutations in centrosomal proteins cause microcephaly. 17, 18 Recently, it has been demonstrated that centrosomal proteins are essential for microtubule organization and centrosome motility that have important roles in axonal formation. 19 ZNF238 is a POZ/zinc finger transcriptional repressor gene. 20 Mice with targeted knock out of ZNF238 display severe hypoplasia of the cerebral cortex and the hippocampus, along with increased apoptosis of progenitors in the ventricular zone. 21 These functional data and the genotypephenotype correlation in our patients implicate deletion of CEP170 and/or ZNF238 as the cause for CCAs. Although our smallest region of overlap is consistent with the critical regions for CCAs previously mapped by Boland et al 8 and Orellana et al, 7 it is centromeric to those mapped by other studies, 1,6,10 implying that the 1q43-q44 region harbors more than one gene important for the development of a normal corpus callosum.
In addition, we describe the first intragenic deletion of AKT3 and the associated phenotypic consequences that include renal abnormalities, a septal heart defect, microcephaly, and developmental delay in the absence of CCA. All patients with deletion of AKT3 had microcephaly, except patient 6. The CNV in patient 6 deletes only the last exon of AKT3, and hence, may lead to residual protein being translated. Although we could not confirm whether the intragenic deletion was de novo, all patients with deletion of AKT3 reported to date have been observed to have microcephaly. The only report of deletion of AKT3 without any phenotypic manifestations is that of an unaffected mother of two children with microcephaly and developmental delay described by van Bon et al. 1 In the same report, the only patient without microcephaly had a deletion that spared AKT3. Both of the existing knock out mouse models of Akt3 deficiency showed postnatal microcephaly. 15, 16 Our data interpreted, along with existing functional data, suggests that AKT3 is indeed important for the normal development of the brain, but not for CCA.
In summary, deletions of 1q43-q44 result in microcephaly, developmental delay, and corpus callosal abnormalities. AKT3 is important for normal brain development, and its haploinsufficiency causes microcephaly, but not corpus callosal abnormalities. Deletion of the novel centrosomal protein CEP170 and/or the zinc finger transcriptional repressor ZNF238 causes corpus callosal abnormalities.
